Enroll in this qualification and you will acquire a complete training for differences in neurodegenerative diseases such as Alzheimer's and vascular cognitive impairment"

Chronic diseases, and in particular Dementias, are becoming increasingly prevalent as a consequence of the progressive population ageing faced by today's societies. However, despite the fact that organizations such as the World Health Organization attach particular importance to these conditions, many of them are underdiagnosed and underestimated. As a result, disorders are rarely accurately diagnosed and, in turn, are not treated with the most appropriate treatment. Nor do they receive the necessary follow-up and, only on very few occasions, are genetic studies carried out to measure their impact on the family line. For this reason, the different levels of medical care are increasingly calling for highly trained professionals to identify risk factors in patients with signs of neurocognitive impairment, to identify the disease early and to provide the necessary care.

Based on these needs, TECH has created a first class academic program. Thus, the Hybrid professional master’s degree in Dementias is composed of two educational moments that will provide different elements to the training of professionals. First, there is a period of theoretical learning through a platform with multiple interactive resources and multimedia products that will strengthen knowledge and update the specialist on disorders such as Alzheimer's, cognitive vascular impairment, Lewy body disease, among others. It will also delve into the latest diagnostic procedures through neuropsychological protocols, biological analysis and clinical imaging tests.

Afterwards, the physician will face a 3-week professional internship in a prestigious healthcare center. During this process, they will have the opportunity to apply all their new skills on real patients and under the careful guidance of the most qualified experts. They will also have an assistant tutor who will be in charge of setting tasks to broaden their skills. Through this stay, TECH graduates will be able to position themselves at the forefront of this health area and offer patients the best guarantees against the most severe Dementias.

For 3 weeks, you will receive personalized advice from an assistant tutor who will help you to directly handle different real cases of patients with Dementias"

This Hybrid professional master’s degree in Dementias contains the most complete and up-to-date scientific program on the market. The most important features include:

• Development of more than 100 clinical cases presented by professionals of Neurology in particular and Medicine in general
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Comprehensive systematized action plans for the main pathologies faced by patients with dementia
• Presentation of practical workshops on diagnostic and therapeutic techniques for patients with Alzheimer's disease, cognitive vascular impairment, Lewy body disease, among others
• An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course
• With a special emphasis on evidence-based medicine and medical research methodologies with respect to dementia disorders
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection
• Furthermore, you will be able to carry out a clinical internship in one of the best hospital centers

A 100% online study stage and an intensive face-to-face stay in prestigious health centers distinguish this study program from other degrees in the educational panorama"

In this Master's proposal, of professionalizing character and hybrid mode, the program is aimed at updating health professionals, dedicated to the care, rehabilitation and readjustment of the social life of patients with dementias. The contents are based on the latest scientific evidence, and oriented in a didactic way to integrate theoretical knowledge in the practice of care, and the theoretical and practical elements will facilitate the updating of knowledge and allow decision making in the management of different cases.

Thanks to its multimedia content elaborated with the latest educational technology, they will allow the medical professional to obtain situated and contextual learning, that is to say, a simulated environment that will provide immersive learning, programmed to train in real situations. This program is designed around Problem-Based Learning, whereby the professional must try to solve the different professional practice situations that arise throughout the program. For this purpose, the students will be assisted by an innovative interactive video system created by renowned and experienced experts.

This syllabus adapts to your schedules and needs, offering you the opportunity to access learning on your own terms and objectives"

This Hybrid professional master’s degree has been designed so that, upon completion, you can join the medical vanguard with a complete vision of the most modern diagnostic procedures with respect to dementias"

The comprehensive curriculum of this degree includes novel methods for the diagnosis of neurodegenerative lesions, vascular and other disorders that can cause the onset of dementia. The academic subjects provide a detailed description of the latest discoveries related to Alzheimer's disease and Lewy body disease. Likewise, the degree will provide the physician with the most recent protocols on the assessment of cognitive impairment for geriatric patients and how to approach their therapy through updated methodologies. All this knowledge will enable graduates of this program to lead the vanguard of care from a practical and theoretical point of view.

Study cognitive impairment and other symptoms of Dementias through the most updated syllabus in the educational market"

Module 1. Alzheimers Disease

1.1. Concept
1.2. Epidemiology
1.3. Risk Factors
1.4. Typical and Atypical Clinical Phenotypes
1.5. Diagnostic Criteria
1.6. Biomarkers in Alzheimer's Disease
1.7. Treatment Focused on Cognition Pharmacological and Non-pharmacological
1.8. Treatment of BPSD
1.9. Future Therapeutic Targets
1.10. Genetic Assessment

Module 2. Vascular Cognitive Impairment

2.1. Concept
2.2. Risk Factors
2.3. Epidemiology
2.4. Diagnostic Criteria
2.5. Clinical Phenotypes
2.6. Neuropsychological Aspects
2.7. Biomarkers in Structural Imaging
2.8. Treatment Focused on Cognition
2.9. Treatment Focused on Behavior
2.10. Non-Pharmacological Treatment

Module 3. Lewy Body Dementia

3.1. Introduction. Lewy Body Dementia Within Synucleinopathies
3.2. Epidemiology
3.3. Clinical and Radiological Diagnostic Criteria Topography of Lesions in Images and their Clinical Expression Differential Diagnosis Based on the Clinical Expression of the Topographic Lesion
3.4. Early and Late Clinical Semiology Clinical Phenotypes
3.5. Diagnostic Approach and Clinical Management of Dysautonomia and the Common Clinical Comorbidities Falls and Fractures Sleep Disorders. Behavioral Disorders
3.6. Pharmacological Treatment Focused on Cognition
3.7. Non-Pharmacological Treatment
3.8. Treatment Focused on Motor Skills
3.9. Pharmacological and Non-pharmacological Treatment Focused on Behavior
3.10. Considerations for Advanced Decision Planning for People with Lewy Body Disease

Module 4. Frontotemporal Dementia

4.1. Concept
4.2. Epidemiology
4.3. Diagnostic Criteria
4.4. Specificity of Cognitive and Behavioral Symptoms

4.4.1. Cognitive Symptoms
4.4.2. Behavioral Symptoms

4.5. Clinical Sub-types

4.5.1. Behavioral Variant DFT
4.5.2. Language Variants
4.5.3. Motor Variants: CBD and PSP
4.5.4. FTD-ALS

4.6. Pharmacological Treatment
4.7. Non-Pharmacological Treatment

Module 5. Neuropsychology in Dementias

5.1. Neuropsychological Assessment of Attention and Memory
5.2. Neuropsychological Evaluation of Language
5.3. Neuropsychological Evaluation of Praxis
5.4. Neuropsychological Evaluation of Visual-spatial Functions
5.5. Neuropsychological Evaluation of Executive Functions
5.6. Behavioral and Functional Evaluation
5.7. Cognitive Patterns in Dementia

5.7.1. Cortical vs. Sub-cortical
5.7.2. Frontotemporal vs. Parieto-Occipital

5.8. Cognitive Rehabilitation
5.9. Bibliographic References

Module 6. Genetic Assessment in Dementias

6.1. Introduction
6.2. Genetics in Alzheimer's Disease

6.2.1. Prevalence
6.2.2. Mendelian Genetics
6.2.3. Susceptibility of Genes
6.2.4. Recommendations in Clinical Practice

6.3. Genetics in Vascular Dementia

6.3.1. Recommendations in Clinical Practice

6.4. Genetics in Fronto-temporal Dementia

6.4.1. Genetics of BVFTD
6.4.2. Genetics in FTD with Parkinsonism
6.4.3. Genetics in FTD-ALS
6.4.4. Genetics of Primary Aphasia
6.4.5. Clinical-Genetic Correlations
6.4.6. Recommendations in Clinical Practice

6.5. Genetics of Prion Diseases

6.5.1. Recommendations in Clinical Practice

6.6. Diagnostic Algorithm

6.6.1. Diagnostic Algorithm in Alzheimer's Disease
6.6.2. Diagnostic Algorithm in FTD

6.7. Genetic Counseling

6.7.1. Concept of Genetic Counseling
6.7.2. Practical Examples PSEN 1 Gene, C9ORF72 Gene, APOE4 Gene, CADASIL Cases, Progranulin Gene

Module 7. Molecular Neuroimaging in Dementias

7.1. Introduction
7.2. Methodological Aspects

7.2.1. Equipment SPECT and PET
7.2.2. Molecular Processes and Radiopharmaceuticals

7.2.2.1. Neuron Activity
7.2.2.2. Dopaminergic Activity
7.2.2.3. Amyloid Deposition
7.2.2.4. Tau Deposit
7.2.2.5. Neuroinflammation

7.2.3. Image Analysis

7.2.3.1. Visual Analysis
7.2.3.2. Comparison with a normality database in surface projections (SSP)
7.2.3.3. Voxel-Based Image Analysis

7.3. Neuroimaging of Alzheimer’s Disease

7.3.1. Mild Cognitive Impairment and Dementia
7.3.2. Atypical Forms

7.4. Neuroimaging in Fronto-temporal Dementia

7.4.1. FTD Variant in Behavior
7.4.2. Primary Aphasias
7.4.3. Others

7.5. Neuroimaging of Dementias with Parkinsonism

7.5.1. Lewy Body Dementia
7.5.2. Progressive Supranuclear Palsy
7.5.3. Corticobasal Degeneration

7.6. Diagnostic Algorithm

7.6.1. Diagnostic Algorithm in Alzheimer's Disease
7.6.2. Diagnostic Algorithm in FTD and Dementia with Parkinsonism

7.7. Case Studies

Module 8. MRI in Dementias

8.1. Introduction
8.2. Diagnostic Algorithm

8.2.1. CT and MRI in Cognitive Impairment Evaluation Classification of Dementias
8.2.2. White Matter Evaluation
8.2.3. Gray Matter Evaluation
8.2.4. Advanced Techniques: Perfusion, Diffusion, Spectroscopy, Functional MRI

8.3. Potentially Treatable Causes of Dementia

8.3.1. Adult Hydrocephalus, Vascular Injuries
8.3.2. Surgical Injuries: Tumors and Subdural Hematoma
8.3.3. Inflammatory and Infectious Lesions

8.4. Alzheimers Disease

8.4.1. Structural MRI: Typical and Atypical Phenotypes
8.4.2. Volumetry: Cortical Thickness and Hippocampi
8.4.3. Perfusion Techniques: Differential Diagnosis
8.4.4. Progression Markers

8.5. Vascular Dementia

8.5.1. Small Vessel Disease
8.5.2. Multi-infarct Dementia
8.5.3. Microhemorrhages SWI Imaging

8.6. Other Degenerative Dementias

8.6.1. Frontotemporal Dementia
8.6.2. Lewy Body Dementia

8.7. Future Perspectives

8.7.1. Functional MRI and Brain Networks
8.7.2. Neuroimaging and Artificial Intelligence

Module 9. Neuropathology in Dementias

9.1. Introduction

9.1.1. Delimitation of the Scope of the Study
9.1.2. Pathogenic Axis for the Interpretation of Histological Findings
9.1.3. Sporadic vs. Genetic Diseases
9.1.4. Diagnostic Criteria vs. Neuropathological Findings

9.2. Levels of Study in Neuropathology

9.2.1. Macroscopic
9.2.2. Histological
9.2.3. Molecular

9.3. Alzheimer's Type Pathology

9.3.1. Macroscopic Findings
9.3.2. Characteristics of Histological Lesions
9.3.3. Beta Amyloid Pathology
9.3.4. TAU Pathology
9.3.5. Diagnostic Criteria and Stages

9.4. Lewy Type Pathology

9.4.1. Macroscopic Findings
9.4.2. Characteristics of Histological Lesions
9.4.3. Lewy Body Dementia: Stages and Subtypes
9.4.4. Lewy Disease as a Combined Pathology

9.5. Tauopathies with Dementia

9.5.1. Molecular Classification of Tauopathies
9.5.2. Progressive Supranuclear Palsy
9.5.3. Argyrophilic Grain Disease
9.5.4. Corticobasal Degeneration
9.5.5. Pick Disease
9.5.6. Other Less Common Tauopathies
9.5.7. Combined Pathology Tauopathies

9.6. Pathology TDP-43

9.6.1. FTLD TDP-43 Classification
9.6.2. Sporadic FTLD
9.6.3. Genetics in FTLD
9.6.4. Hippocampal Sclerosis and LATE

9.7. Rare FTLD and Other Uncommon Pathologies as a Cause of Neurodegenerative Dementia
9.8. Human Prion Diseases

9.8.1. Molecular Pathology of the Prionic Protein
9.8.2. Sporadic Creutzfeldt-Jakob Disease: Molecular Subtypes
9.8.3. Genetic Prionic Diseases
9.8.4. Transmissible Prion Diseases

9.9. Cerebrovascular Pathology and Dementia

9.9.1. Basic Lesions and Assessment Strategy
9.9.2. Post-infarction Dementia
9.9.3. Dementia and Small Vessel Pathology
9.9.4. Cerebrovascular Disease as a Combined Pathology

Module 10. Rapidly Progressive Dementias

10.1. Introduction

10.1.1. Concept
10.1.2. Epidemiology
10.1.3. Differential Diagnosis and Diagnostic Algorithm

10.2. Prion Diseases

10.2.1. Sporadic Creutzfeldt-Jakob Disease
10.2.2. Other Prionopathies: Variant CJD, Gerstmann-Sträussler, Fatal Familial Insomnia, etc

10.3. Infections

10.3.1. H.I.V
10.3.2. Syphilis
10.3.3. Other Infections of the Central Nervous System (Viral Encephalitis, PML, Subacute-Chronic Meningitis)

10.4. Autoimmune Diseases

10.4.1. Antibody-mediated Encephalitis
10.4.2. Hashimoto
10.4.3. Vasculitis of the Central Nervous System
10.4.4. Others (Sarcoidosis, Systemic Vasculitis, etc.)

10.5. Oncology Patients

10.5.1. Tumors of the Central Nervous System
10.5.2. Meningeal Carcinomatosis
10.5.3. Yatrogen (Radiotherapy, Intrathecal Chemotherapy)

10.6. Toxic-Metabolic

10.6.1. Endocrinopathies
10.6.2. Carential
10.6.3. Mitochondrial
10.6.4. Toxic (Alcohol, Metal, Drugs)

Module 11. Comprehensive Geriatric Assessment of the Elderly Person Suffering from Cognitive Impairment or Dementia Clinical and Cognitive Comorbidities Some Aspects of the Advanced Planning which Impact the Clinical Evolution

11.1. Introduction. Elderly Patients with Cognitive Impairment Dementia and the Functional Perspective
11.2. Comorbidities: Elderly Patients Who Suffer From Comorbid Pathologies Which Influence Neurodegeneration and Comorbid Pathologies Which Are Related to Non-Dementia Cognitive Impairment

11.2.1. Polypharmacy and Overprescription
11.2.2. Falls, Walking and Cognition Joint Evaluation of Both Entities
11.2.3. Frailty and Sarcopenia Prescribed Exercise in Elderly People with Cognitive Impairment
11.2.4. Anorexia, Dysphagia, Weight Loss and Refusal to Eat Interaction with cognitive impairment and clinical evolution
11.2.5. Other Geriatric Syndromes
11.2.6. Considerations of advanced planning of care and decision making in elderly patients who suffer from cognitive impairment and dementia

Study cognitive impairment and other symptoms of dementias through the most up-to-date syllabus on the educational market"